314 results on '"Bjørge, Line"'
Search Results
2. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
- Author
-
Barretina-Ginesta, Pilar, Bennett, Katherine, Berek, Jonathan, Berger, Regina, Bjørge, Line, Boere, Ingrid, Brennan, Donal, Bruchim, Ilan, Chang, Ting-Chang, Chavez Blanco, Adriana, Chen, Xiaojun, Colombo, Nicoletta, Crosbie, Emma, Denys, Hannelore, Duska, Linda, Fruehauf, Filip, Gomez Garcia, Eva Maria, van Gorp, Toon, Grimm, Christoph, Guitmann, Gustavo, Han, Kathy, Hanker, Lars, Harano, Kenichi, Hasegawa, Kosei, Herrington, C Simon, Ip, Philip, Joly, Florence, Khaw, Pearly, Kohn, Elise, Kristeleit, Rebecca, Kroep, Judith, Leary, Alexandra, Lee, Jung-Yun, Lheureux, Stephanie, Liu, Jihong, Mackay, Helen, Mahner, Sven, Mariani, Andrea, McAlpine, Jessica, Mikami, Yoshiki, Mirza, Mansoor Raza, Mukhopadhyay, Asima, Nagao, Shoji, Ng, Joseph, Nogueira-Rodrigues, Angelica, Novák, Zoltán, O'Donnell, Jennifer, Osborne, Sherill, Perez-Fidalgo, J. Alejandro, Romeo Marin, Margarita, Roy Chowdhury, Rahul, Sadozye, Azmat, Safra, Tamar, Scott, Claire, Sehouli, Jalid, Slomovitz, Brian, Tan, David, Taylor, Alexandra, Valabrega, Giorgio, Veneziani, Ana, Verhoeven, Karen, Vetter, Marcus, Wampfler, Julian, Westin, Shannon, Wimberger, Pauline, Zola, Paolo, Creutzberg, Carien L, Kim, Jae-Weon, Eminowicz, Gemma, Allanson, Emma, Eberst, Lauriane, Kim, Se Ik, Nout, Remi A, Park, Jeong-Yeol, Lorusso, Domenica, Mileshkin, Linda, Ottevanger, Petronella B, Brand, Alison, Mezzanzanica, Delia, Oza, Amit, Gebski, Val, Pothuri, Bhavana, Batley, Tania, Gordon, Carol, Mitra, Tina, White, Helen, Howitt, Brooke, Matias-Guiu, Xavier, Ray-Coquard, Isabelle, Gaffney, David, Small, William, Jr, Miller, Austin, Concin, Nicole, Powell, Matthew A, Stuart, Gavin, and Bookman, Michael A
- Published
- 2024
- Full Text
- View/download PDF
3. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
- Author
-
Dareng, Eileen O., Coetzee, Simon G., Tyrer, Jonathan P., Peng, Pei-Chen, Rosenow, Will, Chen, Stephanie, Davis, Brian D., Dezem, Felipe Segato, Seo, Ji-Heui, Nameki, Robbin, Reyes, Alberto L., Aben, Katja K.H., Anton-Culver, Hoda, Antonenkova, Natalia N., Aravantinos, Gerasimos, Bandera, Elisa V., Beane Freeman, Laura E., Beckmann, Matthias W., Beeghly-Fadiel, Alicia, Benitez, Javier, Bernardini, Marcus Q., Bjorge, Line, Black, Amanda, Bogdanova, Natalia V., Bolton, Kelly L., Brenton, James D., Budzilowska, Agnieszka, Butzow, Ralf, Cai, Hui, Campbell, Ian, Cannioto, Rikki, Chang-Claude, Jenny, Chanock, Stephen J., Chen, Kexin, Chenevix-Trench, Georgia, Chiew, Yoke-Eng, Cook, Linda S., DeFazio, Anna, Dennis, Joe, Doherty, Jennifer A., Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M., Ene, Gabrielle, Fasching, Peter A., Flanagan, James M., Fortner, Renée T., Fostira, Florentia, Gentry-Maharaj, Aleksandra, Giles, Graham G., Goodman, Marc T., Gronwald, Jacek, Haiman, Christopher A., Håkansson, Niclas, Heitz, Florian, Hildebrandt, Michelle A.T., Høgdall, Estrid, Høgdall, Claus K., Huang, Ruea-Yea, Jensen, Allan, Jones, Michael E., Kang, Daehee, Karlan, Beth Y., Karnezis, Anthony N., Kelemen, Linda E., Kennedy, Catherine J., Khusnutdinova, Elza K., Kiemeney, Lambertus A., Kjaer, Susanne K., Kupryjanczyk, Jolanta, Labrie, Marilyne, Lambrechts, Diether, Larson, Melissa C., Le, Nhu D., Lester, Jenny, Li, Lian, Lubiński, Jan, Lush, Michael, Marks, Jeffrey R., Matsuo, Keitaro, May, Taymaa, McLaughlin, John R., McNeish, Iain A., Menon, Usha, Missmer, Stacey, Modugno, Francesmary, Moffitt, Melissa, Monteiro, Alvaro N., Moysich, Kirsten B., Narod, Steven A., Nguyen-Dumont, Tu, Odunsi, Kunle, Olsson, Håkan, Onland-Moret, N. Charlotte, Park, Sue K., Pejovic, Tanja, Permuth, Jennifer B., Piskorz, Anna, Prokofyeva, Darya, Riggan, Marjorie J., Risch, Harvey A., Rodríguez-Antona, Cristina, Rossing, Mary Anne, Sandler, Dale P., Setiawan, V. Wendy, Shan, Kang, Song, Honglin, Southey, Melissa C., Steed, Helen, Sutphen, Rebecca, Swerdlow, Anthony J., Teo, Soo Hwang, Terry, Kathryn L., Thompson, Pamela J., Vestrheim Thomsen, Liv Cecilie, Titus, Linda, Trabert, Britton, Travis, Ruth, Tworoger, Shelley S., Valen, Ellen, Van Nieuwenhuysen, Els, Edwards, Digna Velez, Vierkant, Robert A., Webb, Penelope M., Weinberg, Clarice R., Weise, Rayna Matsuno, Wentzensen, Nicolas, White, Emily, Winham, Stacey J., Wolk, Alicja, Woo, Yin-Ling, Wu, Anna H., Yan, Li, Yannoukakos, Drakoulis, Zeinomar, Nur, Zheng, Wei, Ziogas, Argyrios, Berchuck, Andrew, Goode, Ellen L., Huntsman, David G., Pearce, Celeste L., Ramus, Susan J., Sellers, Thomas A., Freedman, Matthew L., Lawrenson, Kate, Schildkraut, Joellen M., Hazelett, Dennis, Plummer, Jasmine T., Kar, Siddhartha, Jones, Michelle R., Pharoah, Paul D.P., and Gayther, Simon A.
- Published
- 2024
- Full Text
- View/download PDF
4. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
- Author
-
Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M
- Published
- 2024
- Full Text
- View/download PDF
5. Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model
- Author
-
García de Jalón, Elvira, Kleinmanns, Katrin, Fosse, Vibeke, Davidson, Ben, Bjørge, Line, Haug, Bengt Erik, and McCormack, Emmet
- Published
- 2023
- Full Text
- View/download PDF
6. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
- Author
-
Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Marth, Christian, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Vergote, Ignace, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Candido dos Reis, Francisco Jose, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Paoletti, Xavier, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Bruchim, Ilan, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Enomoto, Takayuki, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Oza, Amit M, Heinzelmann, Viola, Gourley, Charlie, Roxburgh, Patricia, Herrington, C Simon, Glasspool, Ros, Zang, Rongyu, Zhu, Jianqing, Gonzalez-Martin, Antonio, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Stuart, Gavin C E, and Bookman, Michael A
- Published
- 2022
- Full Text
- View/download PDF
7. Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
- Author
-
Barrett, J. James E., Herzog, Chiara, Kim, Yoo-Na, Bartlett, Thomas E., Jones, Allison, Evans, Iona, Cibula, David, Zikan, Michal, Bjørge, Line, Harbeck, Nadia, Colombo, Nicoletta, Howell, Sacha J., Rådestad, Angelique Flöter, Gemzell-Danielsson, Kristina, and Widschwendter, Martin
- Published
- 2022
- Full Text
- View/download PDF
8. Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
- Author
-
Helland, Åslaug, Russnes, Hege G., Fagereng, Gro Live, Al-Shibli, Khalid, Andersson, Yvonne, Berg, Thomas, Bjørge, Line, Blix, Egil, Bjerkehagen, Bodil, Brabrand, Sigmund, Cameron, Marte Grønlie, Dalhaug, Astrid, Dietzel, Dalia, Dønnem, Tom, Enerly, Espen, Flobak, Åsmund, Fluge, Sverre, Gilje, Bjørnar, Gjertsen, Bjørn Tore, Grønberg, Bjørn Henning, Grønås, Kari, Guren, Tormod, Hamre, Hanne, Haug, Åse, Heinrich, Daniel, Hjortland, Geir Olav, Hovig, Eivind, Hovland, Randi, Iversen, Ann-Charlotte, Janssen, Emiel, Kyte, Jon Amund, von der Lippe Gythfeldt, Hedda, Lothe, Ragnhild, Lund, Jo-Åsmund, Meza-Zepeda, Leonardo, Munthe-Kaas, Monica Cheng, Nguyen, Olav Toai Duc, Niehusmann, Pitt, Nilsen, Hilde, Puco, Katarina, Ree, Anne Hansen, Riste, Tonje Bøyum, Semb, Karin, Steinskog, Eli Sihn Samdal, Stensvold, Andreas, Suhrke, Pål, Tennøe, Øyvind, Tjønnfjord, Geir E., Vassbotn, Liv Jorunn, Aas, Eline, Aasebø, Kristine, Tasken, Kjetil, and Smeland, Sigbjørn
- Published
- 2022
- Full Text
- View/download PDF
9. The DNA methylome of cervical cells can predict the presence of ovarian cancer
- Author
-
Barrett, James E., Jones, Allison, Evans, Iona, Reisel, Daniel, Herzog, Chiara, Chindera, Kantaraja, Kristiansen, Mark, Leavy, Olivia C., Manchanda, Ranjit, Bjørge, Line, Zikan, Michal, Cibula, David, and Widschwendter, Martin
- Published
- 2022
- Full Text
- View/download PDF
10. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
- Author
-
Helland, Åslaug, Russnes, Hege G., Fagereng, Gro Live, Al-Shibli, Khalid, Andersson, Yvonne, Berg, Thomas, Bjørge, Line, Blix, Egil, Bjerkehagen, Bodil, Brabrand, Sigmund, Cameron, Marte Grønlie, Dalhaug, Astrid, Dietzel, Dalia, Dønnem, Tom, Enerly, Espen, Flobak, Åsmund, Fluge, Sverre, Gilje, Bjørnar, Gjertsen, Bjørn Tore, Grønberg, Bjørn Henning, Grønås, Kari, Guren, Tormod, Hamre, Hanne, Haug, Åse, Heinrich, Daniel, Hjortland, Geir Olav, Hovig, Eivind, Hovland, Randi, Iversen, Ann-Charlotte, Janssen, Emiel, Kyte, Jon Amund, von der Lippe Gythfeldt, Hedda, Lothe, Ragnhild, Lund, Jo-Åsmund, Meza-Zepeda, Leonardo, Munthe-Kaas, Monica Cheng, Nguyen, Olav Toai Duc, Niehusmann, Pitt, Nilsen, Hilde, Puco, Katarina, Ree, Anne Hansen, Riste, Tonje Bøyum, Semb, Karin, Steinskog, Eli Sihn Samdal, Stensvold, Andreas, Suhrke, Pål, Tennøe, Øyvind, Tjønnfjord, Geir E., Vassbotn, Liv Jorunn, Aas, Eline, Aasebø, Kristine, Tasken, Kjetil, and Smeland, Sigbjørn
- Published
- 2022
- Full Text
- View/download PDF
11. Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
- Author
-
Barrett, James E., Herzog, Chiara, Kim, Yoo-Na, Bartlett, Thomas E., Jones, Allison, Evans, Iona, Cibula, David, Zikan, Michal, Bjørge, Line, Harbeck, Nadia, Colombo, Nicoletta, Howell, Sacha J., Rådestad, Angelique Flöter, Gemzell-Danielsson, Kristina, and Widschwendter, Martin
- Published
- 2022
- Full Text
- View/download PDF
12. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples
- Author
-
Barrett, James E., Herzog, Chiara, Jones, Allison, Leavy, Olivia C., Evans, Iona, Knapp, Susanne, Reisel, Daniel, Nazarenko, Tatiana, Kim, Yoo-Na, Franchi, Dorella, Ryan, Andy, Franks, Joanna, Bjørge, Line, Zikan, Michal, Cibula, David, Harbeck, Nadia, Colombo, Nicoletta, Dudbridge, Frank, Jones, Louise, Sundström, Karin, Dillner, Joakim, Rådestad, Angelique Flöter, Gemzell-Danielsson, Kristina, Pashayan, Nora, and Widschwendter, Martin
- Published
- 2022
- Full Text
- View/download PDF
13. A national precision cancer medicine implementation initiative for Norway
- Author
-
Taskén, Kjetil, Russnes, Hege E. G., Aas, Eline, Bjørge, Line, Blix, Egil S., Enerly, Espen, Fagereng, Gro L., Flobak, Åsmund, Gilje, Bjørnar, Gjertsen, Bjørn T., Guren, Tormod K., Heix, Jutta, Hovig, Eivind, Hovland, Randi, Lønning, Per E., Meza-Zepeda, Leonardo A., Mæhle, Per M., Nilsen, Hilde L., Thoresen, Steinar Ø., Widerberg, Ketil, Smeland, Sigbjørn, and Helland, Åslaug
- Published
- 2022
- Full Text
- View/download PDF
14. Secondary Cytoreductive Surgery in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer: A Systematic Review of Randomized Controlled Trials.
- Author
-
Myhr, Andrea Svennevik, Bjørge, Line, and Torkildsen, Cecilie Fredvik
- Subjects
- *
PLATINUM compounds , *CANCER relapse , *RESEARCH funding , *OVARIAN tumors , *CYTOREDUCTIVE surgery , *TREATMENT effectiveness , *CANCER chemotherapy , *QUALITY of life , *PROGRESSION-free survival , *OVERALL survival - Abstract
Simple Summary: Secondary cytoreductive surgery is a treatment option for patients with relapsed platinum-sensitive epithelial ovarian cancer, yet the precise indications and criteria for patient selection remain to be outlined. Furthermore, the impact on progression-free and overall survival remains unclear. The objective of this systematic review was to determine the precise indications for secondary cytoreductive surgery and to elucidate the factors contributing to favorable outcomes associated with the intervention compared to conventional treatment modalities like standard-of-care chemotherapy. Our review confirmed that secondary cytoreductive surgery maintains morbidity, mortality, and quality of life standards for patients. While the trials included utilized different selection criteria for the procedure, our findings underscore the importance of careful patient selection to improve survival in conjunction with conventional chemotherapy. Secondary cytoreductive surgery is a treatment option for relapsed platinum-sensitive epithelial ovarian cancer, but no clear indications are defined for the procedure. This systematic review aims to establish clear indications and compare outcomes versus standard-of-care chemotherapy. We conducted an electronic literature search across three databases and identified 2033 articles, including three phase 3 randomized controlled trials (RCT). The review adhered to PRISMA 2020 guidelines and was registered in PROSPERO (no. CRD42022379817). Despite varying patient selection methods, surgery plus chemotherapy demonstrated significantly prolonged progression-free survival compared to chemotherapy alone. However, overall survival outcomes were inconsistent: while GOG-0213 did not show extended overall survival, recent studies with stricter defined criteria for surgery (SOC-1 and DESKTOP-III) reported improved overall survival with the addition of surgery. Morbidity and mortality rates were low, with no difference in quality of life between the surgery and no-surgery groups. In conclusion, cytoreductive surgery presents a promising option for recurrent epithelial ovarian cancer treatment. Nonetheless, well-defined selection criteria appear crucial for achieving increased overall survival compared to conventional treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
- Author
-
Torkildsen, Cecilie Fredvik, Austdal, Marie, Jarmund, Anders Hagen, Kleinmanns, Katrin, Lamark, Eva Karin, Nilsen, Elisabeth Berge, Stefansson, Ingunn, Sande, Ragnar Kvie, Iversen, Ann-Charlotte, Thomsen, Liv Cecilie Vestrheim, and Bjørge, Line
- Subjects
PHENOTYPES ,CYTOREDUCTIVE surgery ,THERAPEUTICS ,IMMUNITY ,OVERALL survival ,GLEASON grading system - Abstract
Despite advances in surgical and therapeutic approaches, high-grade serous ovarian carcinoma (HGSOC) prognosis remains poor. Surgery is an indispensable component of therapeutic protocols, as removal of all visible tumor lesions (cytoreduction) profoundly improves the overall survival. Enhanced predictive tools for assessing cytoreduction are essential to optimize therapeutic precision. Patients' immune status broadly reflects the tumor cell biological behavior and the patient responses to disease and treatment. Serum cytokine profiling is a sensitive measure of immune adaption and deviation, yet its integration into treatment paradigms is underexplored. This study is part of the IMPACT trial (NCT03378297) and aimed to characterize immune responses before and during primary treatment for HGSOC to identify biomarkers for treatment selection and prognosis. Longitudinal serum samples from 22 patients were collected from diagnosis until response evaluation. Patients underwent primary cytoreductive surgery or neoadjuvant chemotherapy (NACT) based on laparoscopy scoring. Twenty-seven serum cytokines analyzed by Bio-Plex 200, revealed two immune phenotypes at diagnosis: Immune High with marked higher serum cytokine levels than Immune Low. The immune phenotypes reflected the laparoscopy scoring and allocation to surgical treatment. The five Immune High patients undergoing primary cytoreductive surgery exhibited immune mobilization and extended progression-free survival, compared to the Immune Low patients undergoing the same treatment. Both laparoscopy and cytoreductive surgery induced substantial and transient changes in serum cytokines, with upregulation of the inflammatory cytokine IL-6 and downregulation of the multifunctional cytokines IP-10, Eotaxin, IL-4, and IL-7. Over the study period, cytokine levels uniformly decreased in all patients, leading to the elimination of the initial immune phenotypes regardless of treatment choice. This study reveals distinct pre-treatment immune phenotypes in HGSOC patients that might be informative for treatment stratification and prognosis. This potential novel biomarker holds promise as a foundation for improved assessment of treatment responses in patients with HGSOC. ClinicalTrials.gov Identifier: NCT03378297. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer
- Author
-
Engerud, Hilde, Berg, Hege F., Myrvold, Madeleine, Halle, Mari K., Bjorge, Line, Haldorsen, Ingfrid S., Hoivik, Erling A., Trovik, Jone, and Krakstad, Camilla
- Published
- 2020
- Full Text
- View/download PDF
17. Author Correction: Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis
- Author
-
Berg, Hege F., Hjelmeland, Marta Espevold, Lien, Hilde, Espedal, Heidi, Fonnes, Tina, Srivastava, Aashish, Stokowy, Tomasz, Strand, Elin, Bozickovic, Olivera, Stefansson, Ingunn M., Bjørge, Line, Trovik, Jone, Haldorsen, Ingfrid S., Hoivik, Erling A., and Krakstad, Camilla
- Published
- 2021
- Full Text
- View/download PDF
18. Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis
- Author
-
Berg, Hege F., Hjelmeland, Marta Espevold, Lien, Hilde, Espedal, Heidi, Fonnes, Tina, Srivastava, Aashish, Stokowy, Tomasz, Strand, Elin, Bozickovic, Olivera, Stefansson, Ingunn M., Bjørge, Line, Trovik, Jone, Haldorsen, Ingfrid S., Hoivik, Erling A., and Krakstad, Camilla
- Published
- 2021
- Full Text
- View/download PDF
19. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- Author
-
Mirza, Mansoor Raza, Åvall Lundqvist, Elisabeth, Birrer, Michael J, dePont Christensen, Rene, Nyvang, Gitte-Bettina, Malander, Susanne, Anttila, Maarit, Werner, Theresa L, Lund, Bente, Lindahl, Gabriel, Hietanen, Sakari, Peen, Ulla, Dimoula, Maria, Roed, Henrik, Ør Knudsen, Anja, Staff, Synnöve, Krog Vistisen, Anders, Bjørge, Line, and Mäenpää, Johanna U
- Published
- 2019
- Full Text
- View/download PDF
20. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study
- Author
-
Nené, Nuno R, Reisel, Daniel, Leimbach, Andreas, Franchi, Dorella, Jones, Allison, Evans, Iona, Knapp, Susanne, Ryan, Andy, Ghazali, Shohreh, Timms, John F, Paprotka, Tobias, Bjørge, Line, Zikan, Michal, Cibula, David, Colombo, Nicoletta, and Widschwendter, Martin
- Published
- 2019
- Full Text
- View/download PDF
21. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
- Author
-
Mirza, Mansoor Raza, Bergmann, Troels K., Mau-Sørensen, Morten, Christensen, René dePont, Åvall-Lundqvist, Elisabeth, Birrer, Michael J., Jørgensen, Morten, Roed, Henrik, Malander, Susanne, Nielsen, Flemming, Lassen, Ulrik, Brøsen, Kim, Bjørge, Line, and Mäenpää, Johanna
- Published
- 2019
- Full Text
- View/download PDF
22. DNA methylation signatures to predict the cervicovaginal microbiome status
- Author
-
Nené, Nuno R., Barrett, James, Jones, Allison, Evans, Iona, Reisel, Daniel, Timms, John F., Paprotka, Tobias, Leimbach, Andreas, Franchi, Dorella, Colombo, Nicoletta, Bjørge, Line, Zikan, Michal, Cibula, David, and Widschwendter, Martin
- Published
- 2020
- Full Text
- View/download PDF
23. Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors.
- Author
-
Trichkova, Kremena Petrova, Görtler, Franziska, Bjørge, Line, and Schuster, Cornelia
- Subjects
RISK factors of pneumonia ,IMMUNE checkpoint inhibitors ,MEDICAL information storage & retrieval systems ,MELANOMA ,SYSTEMATIC reviews ,HEPATITIS ,RISK assessment ,DESCRIPTIVE statistics ,RESEARCH funding ,MEDLINE ,COLITIS ,DISEASE risk factors - Abstract
Simple Summary: Malignant melanoma is an aggressive cancer with a globally increasing disease rate. Historically, overall survival has been less than one year for advanced disease with distant metastases. The implementation of immune checkpoint inhibitors has remarkably transformed the therapeutic landscape, yielding 40% to 50% five-year survival rates. However, this improvement comes with a cost, as more than 50% of patients may experience severe side effects. Since there is a lack of validated markers predicting a high risk of severe immune therapy-related side effects, we conducted a systematic literature review to investigate the association between patient baseline characteristics and the risk of serious side effects from immune checkpoint blockade. The highest risk was identified among patients treated with ipilimumab. Yet, available data were insufficient to calculate patient-specific risk for adverse events. This work displays the need to report information about side effects more explicitly. Malignant melanoma is a prevalent and aggressive cancer, with globally increasing incidences. While immune checkpoint inhibitors (ICIs) have prolonged the survival of patients with advanced melanoma over the last decade, this improvement comes with the risk of severe immune-related adverse events (irAEs). This systematic review investigates patient baseline characteristics (BCs) as predictive factors for developing severe gastrointestinal, hepatic, and pulmonary irAEs in patients treated with ipilimumab (anti-CTLA-4) and/or nivolumab/pembrolizumab (anti-PD-1). A systematic literature search was conducted in the Ovid databases MEDLINE and EMBASE on 22 April 2022, following the PRISMA guidelines. Out of 1694 articles, 13 were included in the final analysis. We analyzed BCs and the occurrence of severe colitis, hepatitis, and pneumonitis in 22 treatment arms and 3 treatment groups: anti-CTLA-4 (n = 2904), anti-PD-1 (n = 1301), or combination therapy (n = 822). However, missing data preclude a direct comparison of individual BCs and the association to specific irAEs between studies. Descriptive analysis did not identify any significant association between median age, gender distribution, or performance status and severe colitis, hepatitis, or pneumonitis for any of the three treatment groups. We call for greater transparency and standardization in the reporting of patient-specific irAEs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
- Author
-
Dongre, Harsh Nitin, Elnour, Rammah, Tornaas, Stian, Fromreide, Siren, Thomsen, Liv Cecilie Vestrheim, Kolseth, Ingrid Benedicte Moss, Nginamau, Elisabeth Sivy, Johannessen, Anne Christine, Vintermyr, Olav Karsten, Costea, Daniela Elena, and Bjørge, Line
- Subjects
HUMAN papillomavirus ,SQUAMOUS cell carcinoma ,PROGNOSIS ,BRAF genes ,VULVA ,PROGRESSION-free survival - Abstract
Introduction: Vulva squamous cell carcinoma (VSCC) develops through two separate molecular pathways—one involving high‐risk human papilloma virus infection (HPV‐associated), and the other without HPV infection (HPV‐independent) often involving TP53 mutation. HPV‐associated VSCC generally has a better progression‐free survival than HPV‐independent VSCC. The aim of this study was to determine TP53 mutation status using immunohistochemistry, compare different methods of HPV detection and correlate both with survival in a retrospective cohort of 123 patients with VSCC. Material and methods: Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for HPV infection) was performed on formalin‐fixed paraffin‐embedded tissues from a cohort of surgically treated VSCC patients to identify molecular subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR and HPV mRNA in situ hybridization (ISH). The Pearson chi‐square test and multivariable Cox regression model were used to investigate the association of different parameters with progression‐free survival and disease‐specific survival (DSS), and Kaplan–Meier curves were used to show the association of different parameters with survival. Results: The results of p53 and p16INK4A immunohistochemistry confirmed three VSCC subtypes associated with different prognosis. The TP53 mutation status was identified as an independent prognostic factor of worse progression‐free survival (p = 0.024) after adjustment for FIGO stage. p16INK4A immunohistochemistry, mRNA ISH, and DNA PCR had excellent concordance in terms of HPV detection. According to the multivariable Cox regression model, the presence of hrHPV mRNA correlated significantly with increased progression‐free survival (p = 0.040) and DSS (p = 0.045), after adjustment for other confounders. Conclusions: p53 and p16INK4A immunohistochemistry stratify VSCC cohort into three subtypes with TP53mutated patients having the worst prognosis. The detection of hrHPV mRNA by ISH was an independent predictor of increased survival. Thus, the combined detection of p53 and HPV mRNA might improve risk stratification in VSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.
- Author
-
Vilming, Bente, Dahl, Jørgen Fallås, Bentzen, Anne Gry, Ingebrigtsen, Vibeke Anett, Nilsen, Elisabeth Berge, Vistad, Ingvild, Dørum, Anne, Solheim, Olesya, Bjørge, Line, Zucknick, Manuela, Aune, Guro, and Lindemann, Kristina
- Published
- 2023
- Full Text
- View/download PDF
26. Metabolomics Identifies Placental Dysfunction and Confirms Flt-1 (FMS-Like Tyrosine Kinase Receptor 1) Biomarker Specificity
- Author
-
Austdal, Marie, Silva, Gabriela Brettas, Bowe, Sophie, Thomsen, Liv Cecilie Vestrheim, Tangerås, Line Haugstad, Bjørge, Line, Bathen, Tone Frost, and Iversen, Ann-Charlotte
- Published
- 2019
- Full Text
- View/download PDF
27. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
- Author
-
Hollestelle, Antoinette, van der Baan, Frederieke H., Berchuck, Andrew, Johnatty, Sharon E., Aben, Katja K., Agnarsson, Bjarni A., Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Antoniou, Antonis C., Apicella, Carmel, Arndt, Volker, Arnold, Norbert, Arun, Banu K., Arver, Brita, Ashworth, Alan, Baglietto, Laura, Balleine, Rosemary, Bandera, Elisa V., Barrowdale, Daniel, Bean, Yukie T., Beckmann, Lars, Beckmann, Matthias W., Benitez, Javier, Berger, Andreas, Berger, Raanan, Beuselinck, Benoit, Bisogna, Maria, Bjorge, Line, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Anders, Bojesen, Stig E., Bolla, Manjeet K., Bonanni, Bernardo, Brand, Judith S., Brauch, Hiltrud, Brenner, Hermann, Brinton, Louise, Brooks-Wilson, Angela, Bruinsma, Fiona, Brunet, Joan, Brüning, Thomas, Budzilowska, Agnieszka, Bunker, Clareann H., Burwinkel, Barbara, Butzow, Ralf, Buys, Saundra S., Caligo, Maria A., Campbell, Ian, Carter, Jonathan, Chang-Claude, Jenny, Chanock, Stephen J., Claes, Kathleen B.M., Collée, J. Margriet, Cook, Linda S., Couch, Fergus J., Cox, Angela, Cramer, Daniel, Cross, Simon S., Cunningham, Julie M., Cybulski, Cezary, Czene, Kamila, Damiola, Francesca, Dansonka-Mieszkowska, Agnieszka, Darabi, Hatef, de la Hoya, Miguel, deFazio, Anna, Dennis, Joseph, Devilee, Peter, Dicks, Ed M., Diez, Orland, Doherty, Jennifer A., Domchek, Susan M., Dorfling, Cecilia M., Dörk, Thilo, Silva, Isabel Dos Santos, du Bois, Andreas, Dumont, Martine, Dunning, Alison M., Duran, Mercedes, Easton, Douglas F., Eccles, Diana, Edwards, Robert P., Ehrencrona, Hans, Ejlertsen, Bent, Ekici, Arif B., Ellis, Steve D., Engel, Christoph, Eriksson, Mikael, Fasching, Peter A., Feliubadalo, Lidia, Figueroa, Jonine, Flesch-Janys, Dieter, Fletcher, Olivia, Fontaine, Annette, Fortuzzi, Stefano, Fostira, Florentia, Fridley, Brooke L., Friebel, Tara, Friedman, Eitan, Friel, Grace, Frost, Debra, Garber, Judy, García-Closas, Montserrat, Gayther, Simon A., Gentry-Maharaj, Aleksandra, Gerdes, Anne-Marie, Giles, Graham G., Glasspool, Rosalind, Glendon, Gord, Godwin, Andrew K., Goodman, Marc T., Gore, Martin, Greene, Mark H., Grip, Mervi, Gronwald, Jacek, Gschwantler Kaulich, Daphne, Guénel, Pascal, Guzman, Starr R., Haeberle, Lothar, Haiman, Christopher A., Hall, Per, Halverson, Sandra L., Hamann, Ute, Hansen, Thomas V.O., Harter, Philipp, Hartikainen, Jaana M., Healey, Sue, Hein, Alexander, Heitz, Florian, Henderson, Brian E., Herzog, Josef, T Hildebrandt, Michelle A., Høgdall, Claus K., Høgdall, Estrid, Hogervorst, Frans B.L., Hopper, John L., Humphreys, Keith, Huzarski, Tomasz, Imyanitov, Evgeny N., Isaacs, Claudine, Jakubowska, Anna, Janavicius, Ramunas, Jaworska, Katarzyna, Jensen, Allan, Jensen, Uffe Birk, Johnson, Nichola, Jukkola-Vuorinen, Arja, Kabisch, Maria, Karlan, Beth Y., Kataja, Vesa, Kauff, Noah, Kelemen, Linda E., Kerin, Michael J., Kiemeney, Lambertus A., Kjaer, Susanne K., Knight, Julia A., Knol-Bout, Jacoba P., Konstantopoulou, Irene, Kosma, Veli-Matti, Krakstad, Camilla, Kristensen, Vessela, Kuchenbaecker, Karoline B., Kupryjanczyk, Jolanta, Laitman, Yael, Lambrechts, Diether, Lambrechts, Sandrina, Larson, Melissa C., Lasa, Adriana, Laurent-Puig, Pierre, Lazaro, Conxi, Le, Nhu D., Le Marchand, Loic, Leminen, Arto, Lester, Jenny, Levine, Douglas A., Li, Jingmei, Liang, Dong, Lindblom, Annika, Lindor, Noralane, Lissowska, Jolanta, Long, Jirong, Lu, Karen H., Lubinski, Jan, Lundvall, Lene, Lurie, Galina, Mai, Phuong L., Mannermaa, Arto, Margolin, Sara, Mariette, Frederique, Marme, Frederik, Martens, John W.M., Massuger, Leon F.A.G., Maugard, Christine, Mazoyer, Sylvie, McGuffog, Lesley, McGuire, Valerie, McLean, Catriona, McNeish, Iain, Meindl, Alfons, Menegaux, Florence, Menéndez, Primitiva, Menkiszak, Janusz, Menon, Usha, Mensenkamp, Arjen R., Miller, Nicola, Milne, Roger L., Modugno, Francesmary, Montagna, Marco, Moysich, Kirsten B., Müller, Heiko, Mulligan, Anna Marie, Muranen, Taru A., Narod, Steven A., Nathanson, Katherine L., Ness, Roberta B., Neuhausen, Susan L., Nevanlinna, Heli, Neven, Patrick, Nielsen, Finn C., Nielsen, Sune F., Nordestgaard, Børge G., Nussbaum, Robert L., Odunsi, Kunle, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I., Olson, Janet E., Olson, Sara H., Oosterwijk, Jan C., Orlow, Irene, Orr, Nick, Orsulic, Sandra, Osorio, Ana, Ottini, Laura, Paul, James, Pearce, Celeste L., Pedersen, Inge Sokilde, Peissel, Bernard, Pejovic, Tanja, Pelttari, Liisa M., Perkins, Jo, Permuth-Wey, Jenny, Peterlongo, Paolo, Peto, Julian, Phelan, Catherine M., Phillips, Kelly-Anne, Piedmonte, Marion, Pike, Malcolm C., Platte, Radka, Plisiecka-Halasa, Joanna, Poole, Elizabeth M., Poppe, Bruce, Pylkäs, Katri, Radice, Paolo, Ramus, Susan J., Rebbeck, Timothy R., Reed, Malcolm W.R., Rennert, Gad, Risch, Harvey A., Robson, Mark, Rodriguez, Gustavo C., Romero, Atocha, Rossing, Mary Anne, Rothstein, Joseph H., Rudolph, Anja, Runnebaum, Ingo, Salani, Ritu, Salvesen, Helga B., Sawyer, Elinor J., Schildkraut, Joellen M., Schmidt, Marjanka K., Schmutzler, Rita K., Schneeweiss, Andreas, Schoemaker, Minouk J., Schrauder, Michael G., Schumacher, Fredrick, Schwaab, Ira, Scuvera, Giulietta, Sellers, Thomas A., Severi, Gianluca, Seynaeve, Caroline M., Shah, Mitul, Shrubsole, Martha, Siddiqui, Nadeem, Sieh, Weiva, Simard, Jacques, Singer, Christian F., Sinilnikova, Olga M., Smeets, Dominiek, Sohn, Christof, Soller, Maria, Song, Honglin, Soucy, Penny, Southey, Melissa C., Stegmaier, Christa, Stoppa-Lyonnet, Dominique, Sucheston, Lara, Swerdlow, Anthony, Tangen, Ingvild L., Tea, Muy-Kheng, Teixeira, Manuel R., Terry, Kathryn L., Terry, Mary Beth, Thomassen, Mads, Thompson, Pamela J., Tihomirova, Laima, Tischkowitz, Marc, Toland, Amanda Ewart, Tollenaar, Rob A.E.M., Tomlinson, Ian, Torres, Diana, Truong, Thérèse, Tsimiklis, Helen, Tung, Nadine, Tworoger, Shelley S., Tyrer, Jonathan P., Vachon, Celine M., Van 't Veer, Laura J., van Altena, Anne M., Van Asperen, C.J., van den Berg, David, van den Ouweland, Ans M.W., van Doorn, Helena C., Van Nieuwenhuysen, Els, van Rensburg, Elizabeth J., Vergote, Ignace, Verhoef, Senno, Vierkant, Robert A., Vijai, Joseph, Vitonis, Allison F., von Wachenfeldt, Anna, Walsh, Christine, Wang, Qin, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weischer, Maren, Weitzel, Jeffrey N., Weltens, Caroline, Wentzensen, Nicolas, Whittemore, Alice S., Wilkens, Lynne R., Winqvist, Robert, Wu, Anna H., Wu, Xifeng, Yang, Hannah P., Zaffaroni, Daniela, Pilar Zamora, M., Zheng, Wei, Ziogas, Argyrios, Chenevix-Trench, Georgia, Pharoah, Paul D.P., Rookus, Matti A., Hooning, Maartje J., and Goode, Ellen L.
- Published
- 2016
- Full Text
- View/download PDF
28. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
- Author
-
du Bois, Andreas, Kristensen, Gunnar, Ray-Coquard, Isabelle, Reuss, Alexander, Pignata, Sandro, Colombo, Nicoletta, Denison, Ursula, Vergote, Ignace, del Campo, Jose M, Ottevanger, Petronella, Heubner, Martin, Minarik, Thomas, Sevin, Emmanuel, de Gregorio, Nikolaus, Bidziński, Mariusz, Pfisterer, Jacobus, Malander, Susanne, Hilpert, Felix, Mirza, Mansoor R, Scambia, Giovanni, Meier, Werner, Nicoletto, Maria O, Bjørge, Line, Lortholary, Alain, Sailer, Martin Oliver, Merger, Michael, and Harter, Philipp
- Published
- 2016
- Full Text
- View/download PDF
29. Dyslipidemia and immunological deviation in diagnosed preeclampsia
- Author
-
Jarmund, Anders Hagen, Rossevatn Svoren, Åse Turid, Buer, Signe, Ryssdal, Mariell, Steinkjer, Bjørg, Bjørge, Line, Vestrheim Thomsen, Liv Cecilie, Vanky, Eszter, Giskeødegård, Guro F., and Iversen, Ann-Charlotte
- Published
- 2023
- Full Text
- View/download PDF
30. Distinct immunological development throughout pregnancies complicated with preeclampsia, gestational hypertension, and chronic hypertension
- Author
-
Buer, Signe Haaland, Jarmund, Anders Hagen, Rossevatn Svoren, Åse Turid, Ryssdal, Mariell, Tobiesen Stokkeland, Live Marie, Steinkjer, Bjørg, Bjørge, Line, Løvvik, Tone Shetelig, Stafne, Signe, Moholdt, Trine, Giskeødegård, Guro F., Vanky, Eszter, and Iversen, Ann-Charlotte
- Published
- 2023
- Full Text
- View/download PDF
31. Publisher Correction: Shared heritability and functional enrichment across six solid cancers
- Author
-
Jiang, Xia, Finucane, Hilary K., Schumacher, Fredrick R., Schmit, Stephanie L., Tyrer, Jonathan P., Han, Younghun, Michailidou, Kyriaki, Lesseur, Corina, Kuchenbaecker, Karoline B., Dennis, Joe, Conti, David V., Casey, Graham, Gaudet, Mia M., Huyghe, Jeroen R., Albanes, Demetrius, Aldrich, Melinda C., Andrew, Angeline S., Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Antonenkova, Natalia N., Arnold, Susanne M., Aronson, Kristan J., Arun, Banu K., Bandera, Elisa V., Barkardottir, Rosa B., Barnes, Daniel R., Batra, Jyotsna, Beckmann, Matthias W., Benitez, Javier, Benlloch, Sara, Berchuck, Andrew, Berndt, Sonja I., Bickeböller, Heike, Bien, Stephanie A., Blomqvist, Carl, Boccia, Stefania, Bogdanova, Natalia V., Bojesen, Stig E., Bolla, Manjeet K., Brauch, Hiltrud, Brenner, Hermann, Brenton, James D., Brook, Mark N., Brunet, Joan, Brunnström, Hans, Buchanan, Daniel D., Burwinkel, Barbara, Butzow, Ralf, Cadoni, Gabriella, Caldés, Trinidad, Caligo, Maria A., Campbell, Ian, Campbell, Peter T., Cancel-Tassin, Géraldine, Cannon-Albright, Lisa, Campa, Daniele, Caporaso, Neil, Carvalho, André L., Chan, Andrew T., Chang-Claude, Jenny, Chanock, Stephen J., Chen, Chu, Christiani, David C., Claes, Kathleen B. M., Claessens, Frank, Clements, Judith, Collée, J. Margriet, Correa, Marcia Cruz, Couch, Fergus J., Cox, Angela, Cunningham, Julie M., Cybulski, Cezary, Czene, Kamila, Daly, Mary B., deFazio, Anna, Devilee, Peter, Diez, Orland, Gago-Dominguez, Manuela, Donovan, Jenny L., Dörk, Thilo, Duell, Eric J., Dunning, Alison M., Dwek, Miriam, Eccles, Diana M., Edlund, Christopher K., Edwards, Digna R. Velez, Ellberg, Carolina, Evans, D. Gareth, Fasching, Peter A., Ferris, Robert L., Liloglou, Triantafillos, Figueiredo, Jane C., Fletcher, Olivia, Fortner, Renée T., Fostira, Florentia, Franceschi, Silvia, Friedman, Eitan, Gallinger, Steven J., Ganz, Patricia A., Garber, Judy, García-Sáenz, José A., Gayther, Simon A., Giles, Graham G., Godwin, Andrew K., Goldberg, Mark S., Goldgar, David E., Goode, Ellen L., Goodman, Marc T., Goodman, Gary, Grankvist, Kjell, Greene, Mark H., Gronberg, Henrik, Gronwald, Jacek, Guénel, Pascal, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hamdy, Freddie C., Hamilton, Robert J., Hampe, Jochen, Haugen, Aage, Heitz, Florian, Herrero, Rolando, Hillemanns, Peter, Hoffmeister, Michael, Høgdall, Estrid, Hong, Yun-Chul, Hopper, John L., Houlston, Richard, Hulick, Peter J., Hunter, David J., Huntsman, David G., Idos, Gregory, Imyanitov, Evgeny N., Ingles, Sue Ann, Isaacs, Claudine, Jakubowska, Anna, James, Paul, Jenkins, Mark A., Johansson, Mattias, Johansson, Mikael, John, Esther M., Joshi, Amit D., Kaneva, Radka, Karlan, Beth Y., Kelemen, Linda E., Kühl, Tabea, Khaw, Kay-Tee, Khusnutdinova, Elza, Kibel, Adam S., Kiemeney, Lambertus A., Kim, Jeri, Kjaer, Susanne K., Knight, Julia A., Kogevinas, Manolis, Kote-Jarai, Zsofia, Koutros, Stella, Kristensen, Vessela N., Kupryjanczyk, Jolanta, Lacko, Martin, Lam, Stephan, Lambrechts, Diether, Landi, Maria Teresa, Lazarus, Philip, Le, Nhu D., Lee, Eunjung, Lejbkowicz, Flavio, Lenz, Heinz-Josef, Leslie, Goska, Lessel, Davor, Lester, Jenny, Levine, Douglas A., Li, Li, Li, Christopher I., Lindblom, Annika, Lindor, Noralane M., Liu, Geoffrey, Loupakis, Fotios, Lubiński, Jan, Maehle, Lovise, Maier, Christiane, Mannermaa, Arto, Marchand, Loic Le, Margolin, Sara, May, Taymaa, McGuffog, Lesley, Meindl, Alfons, Middha, Pooja, Miller, Austin, Milne, Roger L., MacInnis, Robert J., Modugno, Francesmary, Montagna, Marco, Moreno, Victor, Moysich, Kirsten B., Mucci, Lorelei, Muir, Kenneth, Mulligan, Anna Marie, Nathanson, Katherine L., Neal, David E., Ness, Andrew R., Neuhausen, Susan L., Nevanlinna, Heli, Newcomb, Polly A., Newcomb, Lisa F., Nielsen, Finn Cilius, Nikitina-Zake, Liene, Nordestgaard, Børge G., Nussbaum, Robert L., Offit, Kenneth, Olah, Edith, Olama, Ali Amin Al, Olopade, Olufunmilayo I., Olshan, Andrew F., Olsson, Håkan, Osorio, Ana, Pandha, Hardev, Park, Jong Y., Pashayan, Nora, Parsons, Michael T., Pejovic, Tanja, Penney, Kathryn L., Peters, Wilbert H. M., Phelan, Catherine M., Phipps, Amanda I., Plaseska-Karanfilska, Dijana, Pring, Miranda, Prokofyeva, Darya, Radice, Paolo, Stefansson, Kari, Ramus, Susan J., Raskin, Leon, Rennert, Gad, Rennert, Hedy S., van Rensburg, Elizabeth J., Riggan, Marjorie J., Risch, Harvey A., Risch, Angela, Roobol, Monique J., Rosenstein, Barry S., Rossing, Mary Anne, De Ruyck, Kim, Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schabath, Matthew B., Schleutker, Johanna, Schmidt, Marjanka K., Setiawan, V. Wendy, Shen, Hongbing, Siegel, Erin M., Sieh, Weiva, Singer, Christian F., Slattery, Martha L., Sorensen, Karina Dalsgaard, Southey, Melissa C., Spurdle, Amanda B., Stanford, Janet L., Stevens, Victoria L., Stintzing, Sebastian, Stone, Jennifer, Sundfeldt, Karin, Sutphen, Rebecca, Swerdlow, Anthony J., Tajara, Eloiza H., Tangen, Catherine M., Tardon, Adonina, Taylor, Jack A., Teare, M. Dawn, Teixeira, Manuel R., Terry, Mary Beth, Terry, Kathryn L., Thibodeau, Stephen N., Thomassen, Mads, Bjørge, Line, Tischkowitz, Marc, Toland, Amanda E., Torres, Diana, Townsend, Paul A., Travis, Ruth C., Tung, Nadine, Tworoger, Shelley S., Ulrich, Cornelia M., Usmani, Nawaid, Vachon, Celine M., Van Nieuwenhuysen, Els, Vega, Ana, Aguado-Barrera, Miguel Elías, Wang, Qin, Webb, Penelope M., Weinberg, Clarice R., Weinstein, Stephanie, Weissler, Mark C., Weitzel, Jeffrey N., West, Catharine M. L., White, Emily, Whittemore, Alice S., Wichmann, H-Erich, Wiklund, Fredrik, Winqvist, Robert, Wolk, Alicja, Woll, Penella, Woods, Michael, Wu, Anna H., Wu, Xifeng, Yannoukakos, Drakoulis, Zheng, Wei, Zienolddiny, Shanbeh, Ziogas, Argyrios, Zorn, Kristin K., Lane, Jacqueline M., Saxena, Richa, Thomas, Duncan, Hung, Rayjean J., Diergaarde, Brenda, McKay, James, Peters, Ulrike, Hsu, Li, García-Closas, Montserrat, Eeles, Rosalind A., Chenevix-Trench, Georgia, Brennan, Paul J., Haiman, Christopher A., Simard, Jacques, Easton, Douglas F., Gruber, Stephen B., Pharoah, Paul D. P., Price, Alkes L., Pasaniuc, Bogdan, Amos, Christopher I., Kraft, Peter, and Lindström, Sara
- Published
- 2019
- Full Text
- View/download PDF
32. Shared heritability and functional enrichment across six solid cancers
- Author
-
Jiang, Xia, Finucane, Hilary K., Schumacher, Fredrick R., Schmit, Stephanie L., Tyrer, Jonathan P., Han, Younghun, Michailidou, Kyriaki, Lesseur, Corina, Kuchenbaecker, Karoline B., Dennis, Joe, Conti, David V., Casey, Graham, Gaudet, Mia M., Huyghe, Jeroen R., Albanes, Demetrius, Aldrich, Melinda C., Andrew, Angeline S., Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Antonenkova, Natalia N., Arnold, Susanne M., Aronson, Kristan J., Arun, Banu K., Bandera, Elisa V., Barkardottir, Rosa B., Barnes, Daniel R., Batra, Jyotsna, Beckmann, Matthias W., Benitez, Javier, Benlloch, Sara, Berchuck, Andrew, Berndt, Sonja I., Bickeböller, Heike, Bien, Stephanie A., Blomqvist, Carl, Boccia, Stefania, Bogdanova, Natalia V., Bojesen, Stig E., Bolla, Manjeet K., Brauch, Hiltrud, Brenner, Hermann, Brenton, James D., Brook, Mark N., Brunet, Joan, Brunnström, Hans, Buchanan, Daniel D., Burwinkel, Barbara, Butzow, Ralf, Cadoni, Gabriella, Caldés, Trinidad, Caligo, Maria A., Campbell, Ian, Campbell, Peter T., Cancel-Tassin, Géraldine, Cannon-Albright, Lisa, Campa, Daniele, Caporaso, Neil, Carvalho, André L., Chan, Andrew T., Chang-Claude, Jenny, Chanock, Stephen J., Chen, Chu, Christiani, David C., Claes, Kathleen B. M., Claessens, Frank, Clements, Judith, Collée, J. Margriet, Correa, Marcia Cruz, Couch, Fergus J., Cox, Angela, Cunningham, Julie M., Cybulski, Cezary, Czene, Kamila, Daly, Mary B., deFazio, Anna, Devilee, Peter, Diez, Orland, Gago-Dominguez, Manuela, Donovan, Jenny L., Dörk, Thilo, Duell, Eric J., Dunning, Alison M., Dwek, Miriam, Eccles, Diana M., Edlund, Christopher K., Edwards, Digna R Velez, Ellberg, Carolina, Evans, D. Gareth, Fasching, Peter A., Ferris, Robert L., Liloglou, Triantafillos, Figueiredo, Jane C., Fletcher, Olivia, Fortner, Renée T., Fostira, Florentia, Franceschi, Silvia, Friedman, Eitan, Gallinger, Steven J., Ganz, Patricia A., Garber, Judy, García-Sáenz, José A., Gayther, Simon A., Giles, Graham G., Godwin, Andrew K., Goldberg, Mark S., Goldgar, David E., Goode, Ellen L., Goodman, Marc T., Goodman, Gary, Grankvist, Kjell, Greene, Mark H., Gronberg, Henrik, Gronwald, Jacek, Guénel, Pascal, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hamdy, Freddie C., Hamilton, Robert J., Hampe, Jochen, Haugen, Aage, Heitz, Florian, Herrero, Rolando, Hillemanns, Peter, Hoffmeister, Michael, Høgdall, Estrid, Hong, Yun-Chul, Hopper, John L., Houlston, Richard, Hulick, Peter J., Hunter, David J., Huntsman, David G., Idos, Gregory, Imyanitov, Evgeny N., Ingles, Sue Ann, Isaacs, Claudine, Jakubowska, Anna, James, Paul, Jenkins, Mark A., Johansson, Mattias, Johansson, Mikael, John, Esther M., Joshi, Amit D., Kaneva, Radka, Karlan, Beth Y., Kelemen, Linda E., Kühl, Tabea, Khaw, Kay-Tee, Khusnutdinova, Elza, Kibel, Adam S., Kiemeney, Lambertus A., Kim, Jeri, Kjaer, Susanne K., Knight, Julia A., Kogevinas, Manolis, Kote-Jarai, Zsofia, Koutros, Stella, Kristensen, Vessela N., Kupryjanczyk, Jolanta, Lacko, Martin, Lam, Stephan, Lambrechts, Diether, Landi, Maria Teresa, Lazarus, Philip, Le, Nhu D., Lee, Eunjung, Lejbkowicz, Flavio, Lenz, Heinz-Josef, Leslie, Goska, Lessel, Davor, Lester, Jenny, Levine, Douglas A., Li, Li, Li, Christopher I., Lindblom, Annika, Lindor, Noralane M., Liu, Geoffrey, Loupakis, Fotios, Lubiński, Jan, Maehle, Lovise, Maier, Christiane, Mannermaa, Arto, Marchand, Loic Le, Margolin, Sara, May, Taymaa, McGuffog, Lesley, Meindl, Alfons, Middha, Pooja, Miller, Austin, Milne, Roger L., MacInnis, Robert J., Modugno, Francesmary, Montagna, Marco, Moreno, Victor, Moysich, Kirsten B., Mucci, Lorelei, Muir, Kenneth, Mulligan, Anna Marie, Nathanson, Katherine L., Neal, David E., Ness, Andrew R., Neuhausen, Susan L., Nevanlinna, Heli, Newcomb, Polly A., Newcomb, Lisa F., Nielsen, Finn Cilius, Nikitina-Zake, Liene, Nordestgaard, Børge G., Nussbaum, Robert L., Offit, Kenneth, Olah, Edith, Olama, Ali Amin Al, Olopade, Olufunmilayo I., Olshan, Andrew F., Olsson, Håkan, Osorio, Ana, Pandha, Hardev, Park, Jong Y., Pashayan, Nora, Parsons, Michael T., Pejovic, Tanja, Penney, Kathryn L., Peters, Wilbert H M., Phelan, Catherine M., Phipps, Amanda I., Plaseska-Karanfilska, Dijana, Pring, Miranda, Prokofyeva, Darya, Radice, Paolo, Stefansson, Kari, Ramus, Susan J., Raskin, Leon, Rennert, Gad, Rennert, Hedy S., van Rensburg, Elizabeth J., Riggan, Marjorie J., Risch, Harvey A., Risch, Angela, Roobol, Monique J., Rosenstein, Barry S., Rossing, Mary Anne, De Ruyck, Kim, Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schabath, Matthew B., Schleutker, Johanna, Schmidt, Marjanka K., Setiawan, V. Wendy, Shen, Hongbing, Siegel, Erin M., Sieh, Weiva, Singer, Christian F., Slattery, Martha L., Sorensen, Karina Dalsgaard, Southey, Melissa C., Spurdle, Amanda B., Stanford, Janet L., Stevens, Victoria L., Stintzing, Sebastian, Stone, Jennifer, Sundfeldt, Karin, Sutphen, Rebecca, Swerdlow, Anthony J., Tajara, Eloiza H., Tangen, Catherine M., Tardon, Adonina, Taylor, Jack A., Teare, M. Dawn, Teixeira, Manuel R., Terry, Mary Beth, Terry, Kathryn L., Thibodeau, Stephen N., Thomassen, Mads, Bjørge, Line, Tischkowitz, Marc, Toland, Amanda E., Torres, Diana, Townsend, Paul A., Travis, Ruth C., Tung, Nadine, Tworoger, Shelley S., Ulrich, Cornelia M., Usmani, Nawaid, Vachon, Celine M., Van Nieuwenhuysen, Els, Vega, Ana, Aguado-Barrera, Miguel Elías, Wang, Qin, Webb, Penelope M., Weinberg, Clarice R., Weinstein, Stephanie, Weissler, Mark C., Weitzel, Jeffrey N., West, Catharine M. L., White, Emily, Whittemore, Alice S., Wichmann, H-Erich, Wiklund, Fredrik, Winqvist, Robert, Wolk, Alicja, Woll, Penella, Woods, Michael, Wu, Anna H., Wu, Xifeng, Yannoukakos, Drakoulis, Zheng, Wei, Zienolddiny, Shanbeh, Ziogas, Argyrios, Zorn, Kristin K., Lane, Jacqueline M., Saxena, Richa, Thomas, Duncan, Hung, Rayjean J., Diergaarde, Brenda, McKay, James, Peters, Ulrike, Hsu, Li, García-Closas, Montserrat, Eeles, Rosalind A., Chenevix-Trench, Georgia, Brennan, Paul J., Haiman, Christopher A., Simard, Jacques, Easton, Douglas F., Gruber, Stephen B., Pharoah, Paul D. P., Price, Alkes L., Pasaniuc, Bogdan, Amos, Christopher I., Kraft, Peter, and Lindström, Sara
- Published
- 2019
- Full Text
- View/download PDF
33. Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study.
- Author
-
Thomsen, Liv Cecilie Vestrheim, Kleinmanns, Katrin, Anandan, Shamundeeswari, Gullaksen, Stein-Erik, Abdelaal, Tamim, Iversen, Grete Alrek, Akslen, Lars Andreas, McCormack, Emmet, and Bjørge, Line
- Subjects
FLOW cytometry ,PILOT projects ,DISEASE progression ,OVARIAN tumors ,CELL physiology ,TREATMENT effectiveness ,RESEARCH funding ,TUMOR markers ,PHENOTYPES ,ALGORITHMS - Abstract
Simple Summary: High-grade serous ovarian cancer (HGSOC) has a dismal prognosis, but its tumor microenvironment (TME), which impacts disease progression and prognosis, is inadequately mapped. A better understanding of the complexity of the TME requires its characterization with multidimensional approaches that allow for simultaneous identification and categorization of the various cell populations. Here, we have performed in-depth profiling of the cellular TME by merging two high-dimensional single-cell datasets generated by mass cytometry of dissociated tumors, to determine whether combining datasets by the CyTOFmerge algorithm can provide more information on the HGSOC TME than separate dataset analyses. The results confirmed high interpatient heterogeneity and that such merging had the potential for identifying novel combinations of markers expressed on cells of the TME. These hypothesis-generating findings could help identify new combinations of expressed antigens and lead to improved mapping of the HGSOC TME and enhanced response to therapy. The prognosis of high-grade serous ovarian carcinoma (HGSOC) is poor, and treatment selection is challenging. A heterogeneous tumor microenvironment (TME) characterizes HGSOC and influences tumor growth, progression, and therapy response. Better characterization with multidimensional approaches for simultaneous identification and categorization of the various cell populations is needed to map the TME complexity. While mass cytometry allows the simultaneous detection of around 40 proteins, the CyTOFmerge MATLAB algorithm integrates data sets and extends the phenotyping. This pilot study explored the potential of combining two datasets for improved TME phenotyping by profiling single-cell suspensions from ten chemo-naïve HGSOC tumors by mass cytometry. A 35-marker pan-tumor dataset and a 34-marker pan-immune dataset were analyzed separately and combined with the CyTOFmerge, merging 18 shared markers. While the merged analysis confirmed heterogeneity across patients, it also identified a main tumor cell subset, additionally to the nine identified by the pan-tumor panel. Furthermore, the expression of traditional immune cell markers on tumor and stromal cells was revealed, as were marker combinations that have rarely been examined on individual cells. This study demonstrates the potential of merging mass cytometry data to generate new hypotheses on tumor biology and predictive biomarker research in HGSOC that could improve treatment effectiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study
- Author
-
Lee, Alice W., Tyrer, Jonathan P., Doherty, Jennifer A., Stram, Douglas A., Kupryjanczyk, Jolanta, Dansonka-Mieszkowska, Agnieszka, Plisiecka-Halasa, Joanna, Spiewankiewicz, Beata, Myers, Emily J., Chenevix-Trench, Georgia, Fasching, Peter A., Beckmann, Matthias W., Ekici, Arif B., Hein, Alexander, Vergote, Ignace, Van Nieuwenhuysen, Els, Lambrechts, Diether, Wicklund, Kristine G., Eilber, Ursula, Wang-Gohrke, Shan, Chang-Claude, Jenny, Rudolph, Anja, Sucheston-Campbell, Lara, Odunsi, Kunle, Moysich, Kirsten B., Shvetsov, Yurii B., Thompson, Pamela J., Goodman, Marc T., Wilkens, Lynne R., Dörk, Thilo, Hillemanns, Peter, Dürst, Matthias, Runnebaum, Ingo B., Bogdanova, Natalia, Pelttari, Liisa M., Nevanlinna, Heli, Leminen, Arto, Edwards, Robert P., Kelley, Joseph L., Harter, Philipp, Schwaab, Ira, Heitz, Florian, du Bois, Andreas, Orsulic, Sandra, Lester, Jenny, Walsh, Christine, Karlan, Beth Y., Hogdall, Estrid, Kjaer, Susanne K., Jensen, Allan, Vierkant, Robert A., Cunningham, Julie M., Goode, Ellen L., Fridley, Brooke L., Southey, Melissa C., Giles, Graham G., Bruinsma, Fiona, Wu, Xifeng, Hildebrandt, Michelle A.T., Lu, Karen, Liang, Dong, Bisogna, Maria, Levine, Douglas A., Weber, Rachel Palmieri, Schildkraut, Joellen M., Iversen, Edwin S., Berchuck, Andrew, Terry, Kathryn L., Cramer, Daniel W., Tworoger, Shelley S., Poole, Elizabeth M., Olson, Sara H., Orlow, Irene, Bandera, Elisa V., Bjorge, Line, Tangen, Ingvild L., Salvesen, Helga B., Krakstad, Camilla, Massuger, Leon F.A.G., Kiemeney, Lambertus A., Aben, Katja K.H., van Altena, Anne M., Bean, Yukie, Pejovic, Tanja, Kellar, Melissa, Le, Nhu D., Cook, Linda S., Kelemen, Linda E., Brooks-Wilson, Angela, Lubinski, Jan, Gronwald, Jacek, Cybulski, Cezary, Jakubowska, Anna, Wentzensen, Nicolas, Brinton, Louise A., Lissowska, Jolanta, Yang, Hannah, Nedergaard, Lotte, Lundvall, Lene, Hogdall, Claus, Song, Honglin, Campbell, Ian G., Eccles, Diana, Glasspool, Rosalind, Siddiqui, Nadeem, Carty, Karen, Paul, James, McNeish, Iain A., Sieh, Weiva, McGuire, Valerie, Rothstein, Joseph H., Whittemore, Alice S., McLaughlin, John R., Risch, Harvey A., Phelan, Catherine M., Anton-Culver, Hoda, Ziogas, Argyrios, Menon, Usha, Ramus, Susan J., Gentry-Maharaj, Aleksandra, Harrington, Patricia, Pike, Malcolm C., Modugno, Francesmary, Rossing, Mary Anne, Ness, Roberta B., Pharoah, Paul D.P., Stram, Daniel O., Wu, Anna H., and Pearce, Celeste Leigh
- Published
- 2015
- Full Text
- View/download PDF
35. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy
- Author
-
Pervaiz, Zahra, Gierman, Lobke, Silva, Gabriela, Skei, Bente, Rakner, Johanne, Beversmark, Anne, Thomsen, Liv, Bjørge, Line, and Iversen, Ann-Charlotte
- Published
- 2019
- Full Text
- View/download PDF
36. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
- Author
-
Lønning, Per E., Berge, Elisabet O., Bjørnslett, Merete, Minsaas, Laura, Chrisanthar, Ranjan, Høberg-Vetti, Hildegunn, Dulary, Cécile, Busato, Florence, Bjørneklett, Silje, Eriksen, Christine, Kopperud, Reidun, Axcrona, Ulrika, Davidson, Ben, Bjørge, Line, Evans, D. Gareth, Howell, Anthony, Salvesen, Helga B., Janszky, Imre, Hveem, Kristian, Romundstad, Pål R., Vatten, Lars J., Tost, Jörg, Dørum, Anne, and Knappskog, Stian
- Published
- 2018
- Full Text
- View/download PDF
37. Molecular and phenotypic characteristics influencing the degree of cytoreduction in high‐grade serous ovarian carcinomas.
- Author
-
Torkildsen, Cecilie Fredvik, Thomsen, Liv Cecilie Vestrheim, Sande, Ragnar Kvie, Krakstad, Camilla, Stefansson, Ingunn, Lamark, Eva Karin, Knappskog, Stian, and Bjørge, Line
- Subjects
NUCLEOTIDE sequencing ,PHENOTYPES ,MEAN platelet volume ,OVARIAN cancer ,CYTOREDUCTIVE surgery ,LOGISTIC regression analysis ,CANCER genetics - Abstract
Background: High‐grade serous ovarian carcinoma (HGSOC) is the deadliest ovarian cancer subtype, and survival relates to initial cytoreductive surgical treatment. The existing tools for surgical outcome prediction remain inadequate for anticipating the outcomes of the complex relationship between tumour biology, clinical phenotypes, co‐morbidity and surgical skills. In this genotype–phenotype association study, we combine phenotypic markers with targeted DNA sequencing to discover novel biomarkers to guide the surgical management of primary HGSOC. Methods: Primary tumour tissue samples (n = 97) and matched blood from a phenotypically well‐characterised treatment‐naïve HGSOC patient cohort were analysed by targeted massive parallel DNA sequencing (next generation sequencing [NGS]) of a panel of 360 cancer‐related genes. Association analyses were performed on phenotypic traits related to complete cytoreductive surgery, while logistic regression analysis was applied for the predictive model. Results: The positive influence of complete cytoreductive surgery (R0) on overall survival was confirmed (p = 0.003). Before surgery, low volumes of ascitic fluid, lower CA125 levels, higher platelet counts and relatively lower clinical stage at diagnosis were all indicators, alone and combined, for complete cytoreduction (R0). Mutations in either the chromatin remodelling SWI_SNF (p = 0.036) pathway or the histone H3K4 methylation pathway (p = 0.034) correlated with R0. The R0 group also demonstrated higher tumour mutational burden levels (p = 0.028). A predictive model was developed by combining two phenotypes and the mutational status of five genes and one genetic pathway, enabling the prediction of surgical outcomes in 87.6% of the cases in this cohort. Conclusion: Inclusion of molecular biomarkers adds value to the pre‐operative stratification of HGSOC patients. A potential preoperative risk stratification model combining phenotypic traits and single‐gene mutational status is suggested, but the set‐up needs to be validated in larger cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study.
- Author
-
Bjørge, Tone, Hjellvik, Vidar, Bjørge, Line, dos‐Santos‐Silva, Isabel, Furu, Kari, Kvåle, Rune, and Engeland, Anders
- Subjects
GYNECOLOGIC cancer ,UTERINE cancer ,CHRONIC diseases ,DRUG utilization ,CANCER patients ,OVARIAN cancer ,CANCER fatigue - Abstract
Objectives: To evaluate both incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer. Design: A prospective study. Setting: Population‐based registries. Population 1.76 million women, including 17 500 women with gynaecological cancers. Methods: Data from the Cancer Registry of Norway was linked to the Norwegian Prescription Database and other national databases. Main Outcome Measures: Prevalence ratios (PRs) and hazard ratios (HRs), with 95% confidence intervals (CIs), of dispensed drugs in gynaecological cancer patients (up to 15 years after diagnosis) were estimated by log‐binomial and Cox regression, respectively, with cancer‐free women as reference. Results: For gynaecological cancer patients, the incidence of drugs used for pain control was higher than in cancer‐free women, especially the first 5 years after diagnosis, and the prevalence was high at least 10 years after. The prevalence of sex hormones was high in women with gynaecological cancer at least 10 years after diagnosis (cervical and ovarian cancer PR = 23, 95% CI 18–30 and PR = 29, 95% CI 15–38, respectively), but low in cancer‐free women (0.3%). Patients with uterine corpus cancer had a higher prevalence of antidiabetics before and at least 10 years after diagnosis, most pronounced in women diagnosed before age 50 (PR = 10, 95% CI 5.0–21). The prevalence of antidepressants was moderately elevated in women with gynaecological cancers. Conclusions: Gynaecological cancer survivors, particularly cervical and ovarian cancer survivors, had an increased long‐term use of drugs for pain control and sex hormones. Survivors of uterine corpus cancer used antidiabetics more often, both before and after diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
- Author
-
May, Taymaa, Bernardini, Marcus, Lheureux, Stephanie, Aben, Katja K.H., Bandera, Elisa V., Beckmann, Matthias W., Benitez, Javier, Berchuck, Andrew, Bjørge, Line, Carney, Michael E., Cramer, Daniel W., deFazio, Anna, Dörk, Thilo, Eccles, Diana M., Friedlander, Michael, García, María Jose, Goode, Ellen L., Hein, Alexander, Høgdall, Claus K., and Jensen, Allan
- Subjects
OVERALL survival ,SURVIVAL rate ,MULTIVARIATE analysis ,PROGRESSION-free survival ,TREATMENT effectiveness - Abstract
Copyright of Canadian Journal of Surgery is the property of CMA Impact Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
40. The WID‐EC test for the detection and risk prediction of endometrial cancer.
- Author
-
Barrett, James E., Jones, Allison, Evans, Iona, Herzog, Chiara, Reisel, Daniel, Olaitan, Adeola, Mould, Tim, MacDonald, Nicola, Doufekas, Konstantinos, Newton, Claire, Crosbie, Emma J., Bjørge, Line, Colombo, Nicoletta, Dostalek, Lukas, Costas, Laura, Peremiquel‐Trillas, Paula, Ponce, Jordi, Matias‐Guiu, Xavier, Zikan, Michal, and Cibula, David
- Subjects
ENDOMETRIAL cancer ,DNA methylation ,CANCER patients ,DISEASE risk factors ,SENSITIVITY & specificity (Statistics) ,ENDOMETRIAL hyperplasia ,GYNECOLOGIC cancer - Abstract
The incidence of endometrial cancer is rising. Measures to identify women at risk and to detect endometrial cancer earlier are required to reduce the morbidity triggered by the aggressive treatment required for advanced endometrial cancer. We developed the WID‐EC (Women's cancer risk IDentification‐Endometrial Cancer) test, which is based on DNA methylation at 500 CpG sites, in a discovery set of cervical liquid‐based cytology samples from 1086 women with and without an endometrial cancer (217 cancer cases and 869 healthy controls) with a worse prognosis (grade 3 or ≥stage IB). We validated the WID‐EC test in an independent external validation set of 64 endometrial cancer cases and 225 controls. We further validated the test in 150 healthy women (prospective set) who provided a cervical sample as part of the routine Swedish cervical screening programme, 54 of whom developed endometrial cancer within 3 years of sample collection. The WID‐EC test identified women with endometrial cancer with a receiver operator characteristic area under the curve (AUC) of 0.92 (95% CI: 0.88‐0.97) in the external set and of 0.82 (95% CI: 0.74‐0.89) in the prospective validation set. Using an optimal cutoff, cancer cases were detected with a sensitivity of 86% and a specificity of 90% in the external validation set, and a sensitivity and specificity of 52% and 98% respectively in the prospective validation set. The WID‐EC test can identify women with or at risk of endometrial cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
- Author
-
Vistad, Ingvild, Bjørge, Line, Solheim, Olesya, Fiane, Bent, Sachse, Kurt, Tjugum, Jostein, Skrøppa, Siri, Bentzen, Anne G., Stokstad, Trine, Iversen, Grete A., Salvesen, Helga B., Kristensen, Gunnar B., and Dørum, Anne
- Published
- 2017
- Full Text
- View/download PDF
42. The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia
- Author
-
Thomsen, Liv Cecilie V., McCarthy, Nina S., Melton, Phillip E., Cadby, Gemma, Austgulen, Rigmor, Nygård, Ottar K., Johnson, Matthew P., Brennecke, Shaun, Moses, Eric K., Bjørge, Line, and Iversen, Ann-Charlotte
- Published
- 2017
- Full Text
- View/download PDF
43. Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins.
- Author
-
Torkildsen, Cecilie Fredvik, Austdal, Marie, Iversen, Ann-Charlotte, Bathen, Tone Frost, Giskeødegård, Guro Fanneløb, Nilsen, Elisabeth Berge, Iversen, Grete Alræk, Sande, Ragnar Kvie, Bjørge, Line, and Thomsen, Liv Cecilie Vestrheim
- Subjects
SEROUS fluids ,NUCLEAR magnetic resonance ,BLOOD lipoproteins ,THERAPEUTICS ,TUMOR treatment ,CARCINOMA ,LIPOPROTEINS - Abstract
High-grade serous ovarian carcinoma (HGSOC) is the most common and deadliest ovarian cancer subtype. Despite advances in treatment, the overall prognosis remains poor. Regardless of efforts to develop biomarkers to predict surgical outcome and recurrence risk and resistance, reproducible indicators are scarce. Exploring the complex tumor heterogeneity, serum profiling of metabolites and lipoprotein subfractions that reflect both systemic and local biological processes were utilized. Furthermore, the overall impact on the patient from the tumor and the treatment was investigated. The aim was to characterize the systemic metabolic effects of primary treatment in patients with advanced HGSOC. In total 28 metabolites and 112 lipoproteins were analyzed by nuclear magnetic resonance (NMR) spectroscopy in longitudinal serum samples (n = 112) from patients with advanced HGSOC (n = 24) from the IMPACT trial with linear mixed effect models and repeated measures ANOVA simultaneous component analysis. The serum profiling revealed treatment-induced changes in both lipoprotein subfractions and circulating metabolites. The development of a more atherogenic lipid profile throughout the treatment, which was more evident in patients with short time to recurrence, indicates an enhanced systemic inflammation and increased risk of cardiovascular disease after treatment. The findings suggest that treatment-induced changes in the metabolome reflect mechanisms behind the diversity in disease-related outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients
- Author
-
Landskron, Johannes, Helland, Øystein, Torgersen, Knut Martin, Aandahl, Einar Martin, Gjertsen, Bjørn Tore, Bjørge, Line, and Taskén, Kjetil
- Published
- 2015
- Full Text
- View/download PDF
45. Pregnancy Outcomes After Paternal Radiofrequency Field Exposure Aboard Fast Patrol Boats
- Author
-
Baste, Valborg, Moen, Bente E., Oftedal, Gunnhild, Strand, Leif Åge, Bjørge, Line, and Mild, Kjell Hansson
- Published
- 2012
46. No effects of MRI scan on male reproduction hormones
- Author
-
Møllerløkken, Ole J., Moen, Bente E., Baste, Valborg, Magerøy, Nils, Oftedal, Gunnhild, Neto, Emanuel, Ersland, Lars, Bjørge, Line, Torjesen, Peter A., and Mild, Kjell Hansson
- Published
- 2012
- Full Text
- View/download PDF
47. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence
- Author
-
Haldorsen, Ingfrid S., Grüner, Renate, Husby, Jenny A., Magnussen, Inger J., Werner, Henrica M. J., Salvesen, Øyvind O., Bjørge, Line, Stefansson, Ingunn, Akslen, Lars A., Trovik, Jone, Taxt, Torfinn, and Salvesen, Helga B.
- Published
- 2013
- Full Text
- View/download PDF
48. A transcriptional profile of the decidua in preeclampsia
- Author
-
Løset, Mari, Mundal, Siv B., Johnson, Matthew P., Fenstad, Mona H., Freed, Katherine A., Lian, Ingrid A., Eide, Irina P., Bjørge, Line, Blangero, John, Moses, Eric K., and Austgulen, Rigmor
- Published
- 2011
49. Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies.
- Author
-
Kleinmanns, Katrin, Gullaksen, Stein-Erik, Bredholt, Geir, Davidson, Ben, Torkildsen, Cecilie Fredvik, Grindheim, Sindre, Bjørge, Line, and McCormack, Emmet
- Subjects
RODENTS ,FLOW cytometry ,OVARIAN tumors ,XENOGRAFTS ,ANIMAL experimentation ,IMMUNE system ,TREATMENT effectiveness ,SURVIVAL analysis (Biometry) ,NIVOLUMAB ,DESCRIPTIVE statistics ,IMMUNOTHERAPY ,MICE ,PHARMACODYNAMICS - Abstract
Simple Summary: Epithelial ovarian cancer (EOC) is a heterogenous disease and new combination therapies are employed to improve treatment, decrease disease recurrence, and avoid the development of treatment resistance. Immunotherapy has been suggested to boost the immune system and improve the prognosis of EOC patients. However, overall low response rates and missing reliable biomarkers to stratify patients to their best-suited personalized treatment regime hinder the successful implementation. Our aim is to advance the development and characterization of humanized patient-derived xenograft models aiding to unravel the function and interaction of the unique tumor microenvironment and the immune system in EOC. These developed and clinically relevant humanized models of EOC have the potential to test various immune cell-targeting combination therapies and identify mechanisms in heterogenous EOC cohorts to ultimately allow patient stratification. High-grade serous ovarian cancer (HGSOC) has poor prognosis and new treatment modalities are needed. Immunotherapy, with checkpoint inhibitors, have demonstrated limited impact. To evaluate the suitability for immunotherapeutics, contextualized preclinical models are required to secure meaningful clinical translation. Therefore, we developed and characterized humanized patient-derived xenograft (hu PDX) murine models of HGSOC, which were established by orthotopic implantation of tumor cell suspensions and intravenous injection of CD34
+ cells isolated from umbilical cord blood samples. The developing human immune system in NSG and NSGS mice was followed longitudinally by flow cytometry and characterized by mass cytometry with a panel of 34 surface markers. Molecular imaging of tumor burden, survival analysis, and characterization of tumor-infiltrating immune cells was performed to assess the treatment response to anti-PD-1 (nivolumab) monotherapy. Successful generation of hu PDX models was achieved. Mice treated with nivolumab showed a decrease in tumor burden, however no significant survival benefit was identified when compared to untreated controls. No correlation was seen between PD-L1 expression and CD8 T cell infiltration and response parameters. As the characterization showed an immune infiltration of predominantly myeloid cells, similar to what is observed in HGSOC patients, the models may have the potential to evaluate the importance of myeloid cell immunomodulation as well. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
50. Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes.
- Author
-
Perrone, Maria Grazia, Vitale, Paola, Miciaccia, Morena, Ferorelli, Savina, Centonze, Antonella, Solidoro, Roberta, Munzone, Cristina, Bonaccorso, Carmela, Fortuna, Cosimo Gianluca, Kleinmanns, Katrin, Bjørge, Line, and Scilimati, Antonio
- Subjects
OVARIAN cancer ,FLUORESCENT probes ,INDUCED ovulation ,CYCLOOXYGENASE inhibitors ,ACETAMIDE derivatives ,PEPTIDE mass fingerprinting ,FLUOROPHORES - Abstract
The identification and removal of all gross and microscopic tumor to render the patient disease free represents a huge challenge in ovarian cancer treatment. The presence of residual disease is an independent negative prognostic factor. Herein, we describe the synthesis and the "in vitro" evaluation of compounds as cyclooxygenase (COX)-1 inhibitors, the COX-1 isoform being an ovarian cancer biomarker, each bearing fluorochromes with different fluorescence features. Two of these compounds N-[4-(9-dimethylimino-9H-benzo[a]phenoxazin-5-ylamino) butyl]-2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetamide chloride (RR11) and 3-(6-(4-(2-(3,4-bis(4-methoxyphenyl)isoxazole-5-yl)acetamido)butyl)amino-6-oxohexyl)-2-[7-(1,3-dihydro-1,1-dimethyl-3-ethyl 2H-benz[e]indolin-2-yl-idene)-1,3,5-heptatrienyl]-1,1-dimethyl-3-(6-carboxilato-hexyl)-1H-benz[e]indolium chloride, 23 (MSA14) were found to be potent and selective inhibitors of cyclooxygenase (COX)-1 "in vitro", and thus were further investigated "in vivo". The IC
50 values were 0.032 and 0.087 µM for RR11 and 23 (MSA 14), respectively, whereas the COX-2 IC50 for RR11 is 2.4 µM while 23 (MSA14) did not inhibit COX-2 even at a 50 µM concentration. Together, this represented selectivity index = 75 and 874, respectively. Structure-based virtual screening (SBVS) performed with the Fingerprints for Ligands and Proteins (FLAP) software allowed both to differentiate highly active compounds from less active and inactive structures and to define their interactions inside the substrate-binding cavity of hCOX1. Fluorescent probes RR11 and 23 (MSA14), were used for preliminary near-infrared (NIR) fluorescent imaging (FLI) in human ovarian cancer (OVCAR-3 and SKOV-3) xenograft models. Surprisingly, a tumor-specific signal was observed for both tested fluorescent probes, even though this signal is not linked to the presence of COX-1. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.